Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Progress in haemophilic care: ethical issues.

E Berntorp1

  • 1Department of Coagulation Disorders, Lund University, Malmö University Hospital, Malmö, Sweden. erik.berntorp@medforsk.mas.lu.se

Haemophilia : the Official Journal of the World Federation of Hemophilia
|May 16, 2002
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Pharmacokinetic modelling and validation of the half-life extension needed to reduce the burden of infusions compared with standard factor VIII.

Haemophilia : the official journal of the World Federation of Hemophilia·2018
Same author

Fifth Åland Island conference on von Willebrand disease.

Haemophilia : the official journal of the World Federation of Hemophilia·2018
Same author

Replacement therapy during surgery in von Willebrand disease needs personalization.

Haemophilia : the official journal of the World Federation of Hemophilia·2018
Same author

Defining extended half-life rFVIII-A critical review of the evidence.

Haemophilia : the official journal of the World Federation of Hemophilia·2018
Same author

Bleeding-related hospitalization in patients with von Willebrand disease and the impact of prophylaxis: Results from national registers in Sweden compared with normal controls and participants in the von Willebrand Disease Prophylaxis Network.

Haemophilia : the official journal of the World Federation of Hemophilia·2018
Same author

Immune tolerance induction: What have we learned over time?

Haemophilia : the official journal of the World Federation of Hemophilia·2018
Same journal

Male Range of Motion Norms in the Haemophilia Joint Health Score Underrepresent the Severity of Joint Damage in Females.

Haemophilia : the official journal of the World Federation of Hemophilia·2026
Same journal

Physical Activity and Sedentary Behaviour in Children With Haemophilia.

Haemophilia : the official journal of the World Federation of Hemophilia·2026
Same journal

Ten-year Demographic and Clinical Characterisation of People With Haemophilia: The Colombian Registry Experience.

Haemophilia : the official journal of the World Federation of Hemophilia·2026
Same journal

Exploratory Claims-Based Assessment of Diagnosed and Potentially Undiagnosed von Willebrand Disease in Japan.

Haemophilia : the official journal of the World Federation of Hemophilia·2026
Same journal

Use of an Oral Health-Related Quality of Life Instrument to Measure Unmet Dental Care Needs in Adults With Inherited Bleeding Disorders.

Haemophilia : the official journal of the World Federation of Hemophilia·2026
Same journal

Clinical Factors for Predicting Synovial Hypertrophy in Early Haemophilic Arthropathy on Prophylaxis: A Cross-Sectional Study of Patient- and Joint-Level Analyses Using Musculoskeletal Ultrasound.

Haemophilia : the official journal of the World Federation of Hemophilia·2026
See all related articles

Advances in hemophilia care, including safer clotting factors and new treatments, have improved patient outcomes. However, challenges remain in concentrate availability, cost-effectiveness, and global access, necessitating ethical considerations and international collaboration.

Area of Science:

  • Hematology
  • Medical Ethics
  • Global Health

Background:

  • Hemophilia patient care has significantly advanced over the last 40-50 years.
  • Safer clotting factor concentrates and sophisticated treatments like prophylaxis and immune-tolerance induction are now available.
  • Despite progress, challenges persist regarding factor concentrate availability and cost-effectiveness.

Purpose of the Study:

  • To review the advancements in hemophilia care.
  • To identify persistent challenges and ethical dilemmas in hemophilia management.
  • To propose solutions for equitable and cost-effective global hemophilia care.

Main Methods:

  • Review of current hemophilia treatment modalities.
  • Analysis of treatment accessibility and cost-effectiveness in different global regions.
Keywords:
Health Care and Public Health

Related Experiment Videos

  • Discussion of ethical considerations related to resource allocation and emerging therapies.

    • Main Results:

    • Significant improvements in hemophilia care have been achieved with safer factor concentrates and advanced treatments.
    • Substantial disparities exist in treatment availability and affordability between developed and developing countries.
    • Ethical dilemmas arise concerning the use of less safe but affordable concentrates and the implementation of novel therapies like gene therapy.

    Conclusions:

    • While hemophilia care has improved, global access and cost-effectiveness remain critical issues.
    • International collaboration, under organizations like the WHO and WFH, is essential to address ethical challenges.
    • Future efforts should focus on evidence-based, cost-effective treatments, health economics studies, and global education initiatives.